Medi­gene, RXi strike re­search deal to im­prove TCRs; Bris­tol-My­ers pays PsiOxus $15M mile­stone for tri­al-ready on­colyt­ic virus

→ A pre­clin­i­cal re­search col­lab­o­ra­tion has brought Marl­bor­ough, MA-based RXi Phar­ma­ceu­ti­cals and Ger­many’s Medi­gene to­geth­er in hopes of im­prov­ing Medi­gene’s adaop­tive T-cell can­cer ther­a­pies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER